The clinical trial Impower010 showed that adjuvant atezolizumab improved overall survival (OS) compared with best supportive care in stage II–IIIA resected NSCLC with high PD-L1 expression, but the PEARLS/KEYNOTE-091 trial did not find a statistically significant benefit of adjuvant pembrolizumab in this setting [6,7]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.